Acumen Pharmaceuticals (ABOS) Net Cash Flow (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Net Cash Flow of -$2.2 million for Q1 2026, down 130.65% sequentially from $7.2 million in Q4 2025, and up 59.89% YoY from -$1.4 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Net Cash Flow (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Net Cash Flow for 7 years, with the latest figure at -$2.2 million in Q1 2026.
- Quarterly Net Cash Flow rose 59.89% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.6 million (up 228.99% YoY) and the FY2025 annual result came in at $18.4 million, up 158.74% from the prior year.
- Net Cash Flow retreated to -$2.2 million in Q1 2026 per ABOS's latest filing, from $7.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $46.5 million in Q3 2022 and troughed at -$52.1 million in Q1 2023.
- A 5-year average of -$4.1 million and a median of -$751000.0 in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow tumbled 465.32% in 2022, then soared 2899.73% in 2024.
- Over 5 years, Net Cash Flow stood at -$27.4 million in 2022, then fell by 2.0% to -$28.0 million in 2023, then soared by 108.71% to $2.4 million in 2024, then surged by 193.4% to $7.2 million in 2025, then plunged by 130.65% to -$2.2 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$2.2 million, $7.2 million, and $10.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 225.59 Mn |
| 10 | Acumen Pharmaceuticals | 237.70 Mn | 237.70 Mn | - | 7.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.65 Mn |
| Jun 30, 2026 | 7.65 Mn |
| Mar 31, 2026 | -2.19 Mn |
| Mar 31, 2026 | -2.19 Mn |
| Dec 31, 2025 | 7.16 Mn |
| Dec 31, 2025 | 7.16 Mn |
| Sep 30, 2025 | 10.02 Mn |
| Sep 30, 2025 | 10.02 Mn |
| Jun 30, 2025 | 6.65 Mn |
| Jun 30, 2025 | 6.65 Mn |
| Mar 31, 2025 | -5.47 Mn |
| Mar 31, 2025 | -5.47 Mn |
| Dec 31, 2024 | 2.44 Mn |
| Dec 31, 2024 | 2.44 Mn |
| Sep 30, 2024 | -34.77 Mn |
| Sep 30, 2024 | -34.77 Mn |
| Jun 30, 2024 | 21.03 Mn |
| Jun 30, 2024 | 21.03 Mn |
| Mar 31, 2024 | -19.96 Mn |
| Mar 31, 2024 | -19.96 Mn |